ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Shares of ImmunoGen Inc (NASDAQ: IMGN) close to doubled this morning after AbbVie Inc (NYSE: ABBV) said it will buy the cancer therapies company for $10.1 billion. ImmunoGen stock priced at a massive premium The all-cash transaction values each share of ImmunoGen at $31.26 – about a 100% premium on their previous close.

ImmunoGen stock nearly doubled on Thursday: what happened?

Snap

VinFast Auto Ltd

The Dow is sprinting to the finish line this November, ahead of a historically bullish month.

Pay Attention to These 3 Stock Movers Today

AbbVie

Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio

MILWAUKEE , Nov. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating ImmunoGen, Inc. (NASDAQ: IMGN) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/immunogen-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether ImmunoGen, Inc. has obtained a Fair Price in its transaction with AbbVie

ImmunoGen (NASDAQ: IMGN ) stock is seeing massive gains on Thursday after the company announced an acquisition deal with AbbVie (NYSE: ABBV ). A press release from AbbVie reveals that ImmunoGen is being acquired for $31.26 per share in cash.

Why Is ImmunoGen (IMGN) Stock Up 81% Today?

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

While the top- and bottom-line numbers for ImmunoGen (IMGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ImmunoGen (IMGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Apple

AMC Entertainment

Amazon

Salesforce

Altamira Therapeutics Ltd

Disney

GameStop

Unlimited HFND Multi-Strategy Return Tracker ETF

Microsoft

Nutanix

NVIDIA

Pure Storage

RedHill Biopharma

Snowflake

Tesla

Ulta Beauty

Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ImmunoGen, Inc. (NASDAQ: IMGN) to AbbVie Inc. for $31.26 per share in cash is fair to ImmunoGen shareholders. Halper Sadeh encourages ImmunoGen shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether ImmunoGen and its.

IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders

AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share.

AbbVie to Acquire ImmunoGen in $10 Billion Deal

AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments.

AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio

AbbVie Inc. ABBV, +0.30% announced Thursday an agreement to buy cancer treatment developer ImmunoGen Inc. IMGN, +0.50% in a cash deal valued at $10.1 billion. Under terms of the agreement, AbbVie will pay $31.26 in cash for each ImmunoGen share outstanding, which represents a 94.6% premium to Wednesday's closing price of $16.06.

AbbVie $10.1 billion deal to buy ImmunoGen values the stock at a 95% premium

Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer ImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populations ImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignancies Transaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billion AbbVie to hold an investor conference call at 8:00 a.m. CT NORTH CHICAGO, Ill.

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

monday.com

Paymentus Holdings

Toyota Motor

W. R. Berkley

TM, PAY, WRB, MNDY and IMGN have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2023.

New Strong Buy Stocks for November 29th

ImmunoGen, Inc. expects to convert the Accelerated Approval of its drug Elahere to "Full Approval" in the 1st half of 2024. Potential European approval of Elahere for treatment of patients with FRa-high platinum-resistant ovarian cancer expected late 2024, with commercialization following after. Full results from the single-arm phase 2 PICCOLO study, using Elahere for the treatment of patients with FRa-high platinum-sensitive ovarian cancer, expected mid-2024.

ImmunoGen: Elahere Data Mid-2024 To Expand Targeted Population

Among the best stocks to buy and watch, ovarian cancer treatment leader ImmunoGen is approaching an early buy point in today's stock market.

Biotech Leader ImmunoGen Eyes Early Buy Point Amid Path To Profitability

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe ImmunoGen (IMGN) Could Rally 52.99%: Here's is How to Trade

AvidXchange Holdings

Brainsway

Brinker International

Rigel Pharmaceuticals

RIGL, BWAY, AVDX, IMGN and EAT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2023.

New Strong Buy Stocks for November 22nd

Modiv

Veeco Instruments

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 16, 2023.:

Best Momentum Stocks to Buy for November 16th

Aquestive Therapeutics Inc

Burford Capital Limited

Guidewire Software

IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.

New Strong Buy Stocks for November 16th

After reaching an important support level, ImmunoGen (IMGN) could be a good stock pick from a technical perspective. IMGN surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

ImmunoGen (IMGN) Just Overtook the 20-Day Moving Average

After reaching an important support level, ImmunoGen (IMGN) could be a good stock pick from a technical perspective. IMGN surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

ImmunoGen (IMGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

Confluent

ICON

Pinterest

Invest in stocks such as Confluent (CFLT), Pinterest (PINS), ICON (ICLR) and ImmunoGen (IMGN) for solid earnings acceleration.

4 Stocks to Invest in for Remarkable Earnings Acceleration

The consensus price target hints at a 40.6% upside potential for ImmunoGen (IMGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 40.58% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?

News for ImmunoGen Stock (IMGN)